688065 凯赛生物
2024/09 - 九个月
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额676,016569,451803,674578,686514,964
投资活动产生之现金流量净额(613,903)(1,558,810)(4,198,216)(110,756)(1,197,232)
筹资活动产生之现金流量净额(413,679)(262,160)403,8782,987,4496,063,446
汇率变动对现金及现金等价物的影响(28,144)40,22159,983(9,185)(2,827)
现金及现金等价物净增加/(减少)(379,710)(1,211,298)(2,930,681)3,446,1935,378,352
期初现金及现金等价物余额5,013,7806,225,0779,155,7585,709,564331,212
期末现金及现金等价物余额4,634,0695,013,7806,225,0779,155,7585,709,564